= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENCE AGREEMENT between THE UNIVERSITY...Licence Agreement • September 28th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH, a charitable body registered in Scotland under registration number SC005336, incorporated under the Universities (Scotland) Acts and having its main administrative offices at Old College, South Bridge Edinburgh, EH8 9YL (the “University”);
LEASE AGREEMENT STELLA LINK INVESTMENTS, LTD. Landlord TO NEUROGENE INC. TenantLease Agreement • September 28th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. MASTER RESEARCH COLLABORATION AGREEMENTMaster Research Collaboration Agreement • September 28th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations
This Master Research Collaboration Agreement (“Agreement”) dated 4 December 2020 (the “Effective Date”) is entered into by and between:
SUBLEASE BETWEEN GPB CAPITAL HOLDINGS, LLC SUBLANDLORD AND NEUROGENE INC. SUBTENANT Subleased Premises: Entire 5th Floor 535 West 24th Street New York, New YorkSublease Agreement • September 28th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations • New York
SUBLEASE (this “Sublease”) made as of the 16th day of May, 2019, by and between GPB CAPITAL HOLDINGS, LLC, having an office York, New York 10011 (“Sublandlord”), and NEUROGENE INC., presently having an office at 434 West 33rd Street, Suite 1102, New York, New York 10001 (“Subtenant”).
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OPTION AGREEMENT between The University...Option Agreement • September 28th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations • England
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH, a charitable body registered in Scotland with registration number SC005336, incorporated under the Universities (Scotland) Acts and having its principal office at Old College, South Bridge, Edinburgh EH8 9YL (“the University”)
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. NON-EXCLUSIVE LICENSE AGREEMENTNon-Exclusive License Agreement • September 28th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS NON-EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of September 30, 2020 (the “Effective Date”), by and between NEUROGENE INC., a Delaware corporation, having offices at 535 W 24th Street, 5th Floor, New York, NY 10011 (“Licensee”), and VIROVEK, INC., a California corporation, having offices at 22429 Hesperian Blvd., Hayward, CA 94541 (“Virovek”) (each a “Party” and collectively the “Parties”).
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • September 28th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations
This exclusive license agreement (“Agreement”) is entered into this 16th day of May, 2019 (the “Effective Date”) between The University of North Carolina at Chapel Hill having an address at 109 Church Street, Chapel Hill, NC, 27516 (“University”) and Neurogene Inc, a corporation having an address at 434 West 33rd Street, New York, NY 10001 (“Licensee”).
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. NON-EXCLUSIVE LICENSE AGREEMENTNon-Exclusive License Agreement • September 28th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations • New York
This Non-Exclusive License Agreement (“Agreement”) is entered by and between Sigma-Aldrich Co. LLC, 3050 Spruce Street, St. Louis, MO 63103, USA (“Sigma”) and (Customer), Neurogene, having an address at 535 W 24th Street, New York, NY 10011 (“(Customer)”). For the purposes of this Agreement, each of Sigma and (Customer) shall be referred to individually as a “Party” and collectively as the “Parties”. The Parties hereto agree as follows:
